📊 BDSX Key Takeaways
Is Biodesix Inc. (BDSX) a Good Investment?
BDSX is a pre-profitability medical diagnostics company with severe operational losses (-30.5% net margin) and negative free cash flow (-$10.2M), despite 24% revenue growth indicating poor earnings quality. Extreme leverage (5.48x Debt/Equity) combined with negative interest coverage and ~2.5 years of cash runway at current burn rates creates significant solvency risk without an imminent profitability inflection.
Biodesix is delivering solid top-line growth, but the business remains deeply unprofitable with a -31.5% operating margin, -39.8% net margin, and materially negative free cash flow. The balance sheet is stressed by negative stockholders' equity, meaningful long-term debt, and weak interest coverage, which makes the current growth profile look low quality until the company proves durable operating leverage and cash burn reduction.
Why Buy Biodesix Inc. Stock? BDSX Key Strengths
- Strong revenue growth of 24.1% YoY demonstrates market demand for diagnostics services
- Adequate near-term liquidity with $25.6M cash and 2.82x current ratio
- Operates in growing medical laboratory services sector with structural tailwinds
- Revenue growth of 24.1% YoY shows continued commercial demand expansion
- Current and quick ratios of 1.86x indicate acceptable near-term liquidity
- EPS improved 29.7% YoY, suggesting losses are narrowing on a per-share basis
BDSX Stock Risks: Biodesix Inc. Investment Risks
- Deeply unprofitable with -30.5% net margin and deteriorating quality of earnings despite revenue growth
- Negative operating cash flow (-$10.2M) and negative free cash flow (-40.1% FCF margin) indicate core business model stress
- Dangerously overleveraged with 5.48x Debt/Equity ratio, $50M long-term debt, and negative interest coverage (-3.1x) preventing debt service from operations
- Limited cash runway of approximately 2.5 years at current burn rate; requires capital raise or profitability inflection
- Negative stockholders' equity indicates a weakened capital structure and limits financial flexibility
- Operating cash flow of -$23.27M and free cash flow of -$23.53M show the business is still consuming cash heavily
- Long-term debt of $50.01M combined with negative interest coverage increases refinancing and solvency risk
Key Metrics to Watch
- Operating cash flow trend and path to positive free cash flow generation
- Gross margin and operating margin expansion toward breakeven
- Debt refinancing success and leverage reduction progress relative to cash burn
- Operating cash flow and free cash flow burn
- Operating margin improvement toward breakeven
Biodesix Inc. (BDSX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.82x current ratio provides a solid financial cushion.
BDSX Profit Margin, ROE & Profitability Analysis
BDSX vs Healthcare Sector: How Biodesix Inc. Compares
How Biodesix Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biodesix Inc. Stock Overvalued? BDSX Valuation Analysis 2026
Based on fundamental analysis, Biodesix Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biodesix Inc. Balance Sheet: BDSX Debt, Cash & Liquidity
BDSX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biodesix Inc.'s revenue has grown significantly by 62% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.64 indicates the company is currently unprofitable.
BDSX Revenue Growth, EPS Growth & YoY Performance
BDSX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $18.0M | -$7.8M | $-0.81 |
| Q3 2025 | $18.2M | -$8.7M | $-1.16 |
| Q2 2025 | $17.9M | -$10.8M | $-0.08 |
| Q1 2025 | $14.8M | -$11.1M | $-0.08 |
| Q3 2024 | $13.5M | -$10.3M | $-0.07 |
| Q2 2024 | $11.9M | -$10.8M | $-0.08 |
| Q1 2024 | $9.1M | -$13.6M | $-0.14 |
| Q3 2023 | $11.1M | -$10.9M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biodesix Inc. Dividends, Buybacks & Capital Allocation
BDSX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biodesix Inc. (CIK: 0001439725)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BDSX
What is the AI rating for BDSX?
Biodesix Inc. (BDSX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BDSX's key strengths?
Claude: Strong revenue growth of 24.1% YoY demonstrates market demand for diagnostics services. Adequate near-term liquidity with $25.6M cash and 2.82x current ratio. ChatGPT: Revenue growth of 24.1% YoY shows continued commercial demand expansion. Current and quick ratios of 1.86x indicate acceptable near-term liquidity.
What are the risks of investing in BDSX?
Claude: Deeply unprofitable with -30.5% net margin and deteriorating quality of earnings despite revenue growth. Negative operating cash flow (-$10.2M) and negative free cash flow (-40.1% FCF margin) indicate core business model stress. ChatGPT: Negative stockholders' equity indicates a weakened capital structure and limits financial flexibility. Operating cash flow of -$23.27M and free cash flow of -$23.53M show the business is still consuming cash heavily.
What is BDSX's revenue and growth?
Biodesix Inc. reported revenue of $25.6M.
Does BDSX pay dividends?
Biodesix Inc. does not currently pay dividends.
Where can I find BDSX SEC filings?
Official SEC filings for Biodesix Inc. (CIK: 0001439725) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BDSX's EPS?
Biodesix Inc. has a diluted EPS of $-0.81.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BDSX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Biodesix Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BDSX stock overvalued or undervalued?
Valuation metrics for BDSX: ROE of -85.3% (sector avg: 15%), net margin of -30.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BDSX stock in 2026?
Our dual AI analysis gives Biodesix Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BDSX's free cash flow?
Biodesix Inc.'s operating cash flow is $-10.2M, with capital expenditures of $81.0K. FCF margin is -40.1%.
How does BDSX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -30.5% (avg: 12%), ROE -85.3% (avg: 15%), current ratio 2.82 (avg: 2).
Is Biodesix Inc. carrying too much debt?
BDSX has a debt-to-equity ratio of 5.48x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.82 suggests adequate short-term liquidity.